Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2025 | $34.00 → $48.00 | Buy | Citigroup |
| 6/11/2025 | $30.00 | Buy | H.C. Wainwright |
| 6/11/2025 | $35.00 → $32.00 | Buy | Citigroup |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 10/21/2024 | $9.00 → $27.00 | Equal Weight → Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $25.00 | Neutral → Buy | Guggenheim |
| 3/27/2024 | Buy → Neutral | Guggenheim |
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
144 - Travere Therapeutics, Inc. (0001438533) (Subject)
10-Q - Travere Therapeutics, Inc. (0001438533) (Filer)
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million Retired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation 2025 KDIGO guidelines and streamlined REMS monitoring strengthen FILSPARI's position as a foundational, nephroprotective therapy for IgAN Company well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26 Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical
Late-breaking poster from DUPLEX Study shows more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan, correlating with reduced kidney failure risk in FSGS Data presentations highlight biomarker and cardiovascular safety data from SPARTAN Study of FILSPARI in patients with IgAN Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9. In focal segmental glomerulosclerosis (FSGS), the Company will present: A late-breaking analysis from the DUPLEX Study demonstra
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $48.00 from $34.00 previously
H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00
Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously
Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics
U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million Retired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation 2025 KDIGO guidelines and streamlined REMS monitoring strengthen FILSPARI's position as a foundational, nephroprotective therapy for IgAN Company well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26 Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical
U.S. net product sales of FILSPARI® (sparsentan) grew 165% year-over-year to $71.9 million in 2Q 2025; 745 new PSFs received in the quarter sNDA seeking full approval of FILSPARI for FSGS accepted for review; PDUFA target action date set for January 13, 2026 Total revenue for 2Q 2025 was $114.4 million, including net product sales of $94.8 million Cash, cash equivalents, and marketable securities totaled approximately $319.5 million as of June 30, 2025 Travere Therapeutics, Inc., (NASDAQ:TVTX) today reported its second quarter 2025 financial results and provided a corporate update. "We continue to make strong progress against our strategic priorities, putting Travere on a trajecto